In the past decade, many studies focused on the immunotherapy of various cancers, which show the benefits from inhibiting the interaction between programmed death-1 (PD-1) and its ligand-1 (PD-L1) to inhibit the suppression of T cell immune responses (3). This evidence concerns the gene PDCD1 and cancer.